Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Bayer Yakuhin Negotiating with Universities, Institutions for Research Agreements
April 9, 2015
- Merck KGaA, Pfizer to Copromote Xalkori in Japan, US, Europe
April 9, 2015
- Bayer Yakuhin Logs Double-Digit Growth for 2 Years Running on Xarelto
April 8, 2015
- BIKEN, Osaka University Strike License Agreement to Develop Novel Pneumococcal Vaccines
April 8, 2015
- Drug Makers Setting Up Medical Affairs Units Independent of Sales Teams
April 7, 2015
- Mochida Using “Granular Tablets” to Gain Share in Generic Drug Market
April 7, 2015
- Pfizer Japan Rolls Out Japan’s 1st Propecia Generic
April 7, 2015
- Biogen Idec Japan Names Steve Sugino, Former Sanofi Diabetes Head, as President
April 7, 2015
- Xtandi Significantly Prolongs PFS vs. Bicalutamide in US: Astellas
April 6, 2015
- Zelboraf a Promising New Treatment Option for Malignant Melanoma: Dr Yamazaki
April 6, 2015
- Takeda Initiates Voluntary Recall of Liovel Combination Tablets LD
April 6, 2015
- Novartis, PeptiDream Conclude License Deal for Drug Discovery Platform Technology
April 6, 2015
- Eisai, Niigata Univ. Finds Correlation of Cognitive Function with Plasma Desmosterol Levels in Alzheimer’s Disease Patients
April 6, 2015
- Astellas Signs Option Deal with US Cancer Center for Monoclonal Antibody Drug for Acute Myeloid Leukemia
April 6, 2015
- Kaken Licenses Topical Hyperhidrosis Treatment from US Biotech
April 3, 2015
- Sanofi Japan Sales Dip 7.6% on Generic Erosion though Plavix Grew
April 3, 2015
- Mochida Unveils New 3-Year Biz Targets, Price Revisions, Generic Penetration Weigh
April 2, 2015
- Kenichi Fujita Becomes President of Taisho Toyama
April 2, 2015
- Eli Lilly to Solely Distribute Cymbalta; Shionogi to Enhance Detailing Activities
April 2, 2015
- MTPC Licenses VMAT2 Inhibitor from Neurocrine Biosciences
April 2, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…